Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.69 AUD | -1.43% | 0.00% | +58.62% |
Feb. 21 | Genetic Signatures Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Jan. 24 | Genetic Signatures Completes Rights Issue | MT |
Sales 2024 * | 10.1M 6.48M | Sales 2025 * | 26.2M 16.81M | Capitalization | 129M 82.56M |
---|---|---|---|---|---|
Net income 2024 * | -17M -10.91M | Net income 2025 * | -6M -3.85M | EV / Sales 2024 * | 10.8 x |
Net cash position 2024 * | 20M 12.83M | Net cash position 2025 * | 7M 4.49M | EV / Sales 2025 * | 4.64 x |
P/E ratio 2024 * |
-7.34
x | P/E ratio 2025 * |
-19.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.08% |
1 day | -1.43% | ||
Current month | +1.47% | ||
1 month | +9.52% | ||
3 months | +39.39% | ||
6 months | +46.81% | ||
Current year | +58.62% |
Managers | Title | Age | Since |
---|---|---|---|
John Melki
CEO | Chief Executive Officer | - | 02-12-31 |
Karl Pechmann
DFI | Director of Finance/CFO | - | 23-06-25 |
Douglas Millar
CTO | Chief Tech/Sci/R&D Officer | - | 01-02-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Anthony Radford
BRD | Director/Board Member | - | 15-09-14 |
Caroline Waldron
BRD | Director/Board Member | - | 22-05-12 |
Michael Aicher
BRD | Director/Board Member | 64 | 14-01-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 0.69 | -1.43% | 40,185 |
24-04-17 | 0.7 | 0.00% | 18 |
24-04-16 | 0.7 | +0.72% | 49,061 |
24-04-15 | 0.695 | +0.72% | 8,874 |
24-04-12 | 0.69 | -0.72% | 56,672 |
Delayed Quote Australian S.E., April 19, 2024 at 01:59 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+58.62% | 84.06M | |
+2.64% | 207B | |
+1.80% | 175B | |
+8.59% | 132B | |
+16.47% | 99.1B | |
-3.42% | 60.89B | |
+12.71% | 52.04B | |
-6.61% | 45.48B | |
-4.53% | 38.81B | |
+9.27% | 38.77B |
- Stock Market
- Equities
- GSS Stock